In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.

Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.

After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.

Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.

A systematic review of dozens of research papers has found that ketamine therapy has a quick, short-term effect of reducing depression symptoms and suicidal thoughts, making it a promising mental health treatment alternative.

The Military Mental Health Crisis affects over 1 million veterans and has claimed 115,000+ lives in the past 20 years. Fortunately, there is finally hope.

MindMed announces that the FDA has placed “clinical hold” on its initial IND submission in preparation for its Phase 2b clinical trial for generalized anxiety disorder (GAD).

In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.

Novamind announces a definitive agreement to acquire Arizona-based Foundations for Change, PLC.

Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.